Protagonist Therapeutics, Inc.

NasdaqGM:PTGX Stock Report

Market Cap: US$5.5b

Protagonist Therapeutics Management

Management criteria checks 3/4

Protagonist Therapeutics' CEO is Dinesh Patel, appointed in Dec 2008, has a tenure of 17.08 years. total yearly compensation is $9.47M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 0.5% of the company’s shares, worth $27.30M. The average tenure of the management team and the board of directors is 5 years and 11 years respectively.

Key information

Dinesh Patel

Chief executive officer

US$9.5m

Total compensation

CEO salary percentage7.19%
CEO tenure17.1yrs
CEO ownership0.5%
Management average tenure5yrs
Board average tenure11yrs

Recent management updates

Recent updates

Why Johnson & Johnson Is Eyeing Protagonist Therapeutics: The Rationale

Oct 13

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues

Oct 11
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues

Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27%

Jun 13
Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27%

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Mar 11

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up

Mar 11
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Jan 13

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Oct 16

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

Protagonist: Too Many Red Flags

Jun 08

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

CEO Compensation Analysis

How has Dinesh Patel's remuneration changed compared to Protagonist Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

US$46m

Jun 30 2025n/an/a

US$52m

Mar 31 2025n/an/a

US$56m

Dec 31 2024US$9mUS$681k

US$275m

Sep 30 2024n/an/a

US$171m

Jun 30 2024n/an/a

US$170m

Mar 31 2024n/an/a

US$162m

Dec 31 2023US$7mUS$655k

-US$79m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$138m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$6mUS$630k

-US$127m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$600k

-US$126m

Sep 30 2021n/an/a

-US$108m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$2mUS$565k

-US$66m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$83m

Dec 31 2019US$2mUS$545k

-US$77m

Compensation vs Market: Dinesh's total compensation ($USD9.47M) is about average for companies of similar size in the US market ($USD8.28M).

Compensation vs Earnings: Dinesh's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Dinesh Patel (68 yo)

17.1yrs
Tenure
US$9,473,819
Compensation

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He serves as Additional Non-Execu...

Leadership Team

NamePositionTenureCompensationOwnership
Dinesh Patel
CEO, President17.1yrsUS$9.47m0.50%
$ 27.3m
Asif Ali
Executive VP & CFO3.8yrsUS$2.81m0.013%
$ 724.3k
Suneel Gupta
Executive Vice President of Clinical Development1yrUS$2.74m0.39%
$ 21.3m
Arturo Molina
Chief Medical Officer3.2yrsUS$3.46m0.026%
$ 1.4m
Mohammad Masjedizadeh
Executive VP & CTO5yrsno datano data
Newman Yeilding
Executive VP1.4yrsno datano data
Matthew Gosling
Executive VP and Chief Legal & Business Officer5.3yrsno datano data
Carena Spivey
Senior VP & Chief Human Resources Officer5yrsno datano data
Ashok Bhandari
EVP & Chief Discovery Officer5yrsno datano data
Carter King
Executive Vice President of Business Development4.8yrsno datano data
Abha Bommireddi
Executive VP & Chief of Staff5yrsno datano data
Samuel Saks
Clinical Development Advisor5yrsno datano data
5.0yrs
Average Tenure
63.5yo
Average Age

Experienced Management: PTGX's management team is seasoned and experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dinesh Patel
CEO, President17.1yrsUS$9.47m0.50%
$ 27.3m
Harlan Weisman
Clinical Advisor11yrsno datano data
Lewis Williams
Independent Director8.6yrsUS$530.48k0%
$ 0
Chaitan Khosla
Chairman of Scientific Advisory Board11yrsUS$188.07kno data
Harold Selick
Independent Chairman16.9yrsUS$571.73k0.062%
$ 3.4m
William Waddill
Independent Director9.5yrsUS$540.48k0.0082%
$ 447.5k
Charles Craik
Scientific Advisorno datano datano data
Mark Gallop
Scientific Advisorno datano datano data
Wayne Lencer
Clinical Advisorno datano datano data
Aida Habtezion
Clinical Advisorno datano datano data
Ellen Scherl
Clinical Advisorno datano datano data
Bryan Giraudo
Independent Director7.7yrsUS$532.98k0.029%
$ 1.6m
11.0yrs
Average Tenure
68yo
Average Age

Experienced Board: PTGX's board of directors are seasoned and experienced ( 11 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/04 14:01
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Protagonist Therapeutics, Inc. is covered by 22 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Mayur SomaiyaBMO Capital Markets Equity Research
Evan SeigermanBMO Capital Markets Equity Research